Plachouri K- M, Chourdakis V, Georgiou S
Dermatology Department, University General Hospital of Patras, Rio, Greece.
Drugs Today (Barc). 2019 Sep;55(9):587-593. doi: 10.1358/dot.2019.55.9.3020159.
Generalized pustular psoriasis (GPP) is a severe psoriasis form that can be refractory to several systemic treatments. The role of interleukin (IL)-17/ T-helper 17 (Th17) axis inhibitors in the therapy of GPP is not fully established. The objective of this paper is to summarize the existing information on the efficacy and safety of secukinumab, ixekizumab and brodalumab in GPP. Articles published in the English language and derived from the databases MEDLINE (PubMed), Embase and Scopus were assessed for this study. Although the existing data on the potential therapeutic benefit of these agents in the treatment of GPP are encouraging, further studies are needed so as to provide sufficient evidence for their use in this serious condition.
泛发性脓疱型银屑病（GPP）是一种严重的银屑病类型，对多种全身治疗可能无效。白细胞介素（IL）-17/辅助性T细胞17（Th17）轴抑制剂在GPP治疗中的作用尚未完全明确。本文的目的是总结司库奇尤单抗、依奇珠单抗和布罗达单抗治疗GPP的疗效和安全性的现有信息。本研究评估了从MEDLINE（PubMed）、Embase和Scopus数据库中检索到的英文发表文章。尽管这些药物治疗GPP的潜在治疗益处的现有数据令人鼓舞，但仍需要进一步研究，以便为其在这种严重疾病中的应用提供充分证据。
